Flurpiridaz F-18 PET心肌灌注显像在疑似冠心病患者中的应用
本研究为第二项3期前瞻性多中心临床研究,纳入730例疑似冠心病患者,评估Flurpiridaz F-18 PET心肌灌注显像诊断冠心病(以定量有创冠状动脉造影≥50%狭窄为定义)的效能与安全性。Flurpiridaz PET满足研究疗效终点,其敏感性和特异性在3位阅片者中有2位显著高于预设阈值;PET敏感性高于SPECT(80.3% vs 68.7%;P=0.0003),特异性非劣于SPECT(63.8% vs 61.7%;P=0.0004)。Flurpiridaz PET在总体人群、女性和肥胖患者中ROC曲线下面积均高于SPECT(P<0.001),且在灌注缺损大小/严重程度评估、图像质量、诊断确定性及辐射暴露方面均优于SPECT。
要点
- Flurpiridaz PET诊断冠心病敏感性高于SPECT(80.3% vs 68.7%),特异性非劣于SPECT(63.8% vs 61.7%)。
- Flurpiridaz PET在总体人群、女性和肥胖患者中ROC曲线下面积均高于SPECT(P<0.001)。
- Flurpiridaz PET在灌注缺损评估、图像质量、诊断确定性及辐射暴露方面均优于SPECT。
核心结论
- Flurpiridaz PET心肌灌注显像可作为检测冠心病的新示踪剂,尤其在女性和肥胖患者中具有应用价值。
研究设计与样本
- 第二项3期前瞻性多中心临床研究,纳入美国、加拿大和欧洲48个中心的730例疑似冠心病患者。
- 患者在接受有创冠状动脉造影前完成1天静息/负荷Flurpiridaz PET和1或2天静息-负荷Tc-99m SPECT。
- PET和SPECT图像由3位对临床及有创冠状动脉造影数据设盲的专家判读。
主要发现
- 共578例患者可评估,年龄63.7±9.5岁,32.5%为女性,52.3%体重指数≥30 kg/m2,33.6%患有糖尿病。
- Flurpiridaz PET满足研究疗效终点,其敏感性和特异性在3位阅片者中有2位显著高于预设阈值。
- Flurpiridaz PET敏感性高于SPECT(80.3% vs 68.7%;P=0.0003),特异性非劣于SPECT(63.8% vs 61.7%;P=0.0004)。
- Flurpiridaz PET的ROC曲线下面积在总体人群(0.80 vs 0.68;P<0.001)、女性和肥胖患者中均高于SPECT(P<0.001)。
- Flurpiridaz PET在灌注缺损大小/严重程度评估、图像质量、诊断确定性和辐射暴露方面均优于SPECT(P<0.001),且安全耐受良好。
关键数值与推荐
- 冠心病定义为定量有创冠状动脉造影显示≥50%狭窄。
临床怎么用
- 对于疑似冠心病患者,尤其是女性和肥胖患者,可考虑使用Flurpiridaz PET心肌灌注显像进行诊断评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Flurpiridaz F-18 (flurpiridaz) is a novel positron emission tomography (PET) myocardial perfusion imaging tracer. OBJECTIVES: The purpose of this study was to further assess the diagnostic efficacy and safety of flurpiridaz for the detection and evaluation of coronary artery disease (CAD) defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA). METHODS: In this second phase 3 prospective multicenter clinical study, 730 patients with suspected CAD from 48 clinical sites in the United States, Canada, and Europe were enrolled. Patients underwent 1-day rest/stress flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled single photon emission computed tomography (SPECT) before ICA. PET and SPECT images were read by 3 experts blinded to clinical and ICA data. RESULTS: A total of 578 patients (age 63.7 ± 9.5 years) were evaluable; 32.5% were women, 52.3% had body mass index ≥30 kg/m2, and 33.6% had diabetes. Flurpiridaz PET met the efficacy endpoints of the study; its sensitivity and specificity were significantly higher than the prespecified threshold value by 2 of the 3 readers. The sensitivity of flurpiridaz PET was higher than SPECT (80.3% vs 68.7%; P = 0.0003) and its specificity was noninferior to SPECT (63.8% vs 61.7%; P = 0.0004). PET area under the receiver-operating characteristic curves were higher than SPECT in the overall population (0.80 vs 0.68; P < 0.001), women, and obese patients (P < 0.001 for both). Flurpiridaz PET was superior to SPECT (P < 0.001) for perfusion defect size/severity evaluation, image quality, diagnostic certainty, and radiation exposure. Flurpiridaz PET was safe and well tolerated. CONCLUSIONS: This second flurpiridaz PET myocardial perfusion imaging trial shows that flurpiridaz has utility as a new tracer for CAD detection, specifically in women and obese patients. (An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]; NCT03354273).
引用
- Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease. J Am Coll Cardiol. 2023. PMID: 37821170. doi:10.1016/j.jacc.2023.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。